Unveiling the molecular and immunological drivers of antibody-drug conjugates in cancer treatment
{{output}}
After decades of investment, antibody-drug conjugates (ADCs) are finally demonstrating their potential, marked by a growing number of clinical approvals, applications in earlier lines of treatment and integration into drug combinations, including immunotherapi... ...
